Adimab, LLC announced the expansion of its existing research collaborations with Merck and Lilly. The latest agreement provides Merck expanded access to Adimab's technology to discover and optimize fully human antibody candidates, including potentially bispecific antibody candidates, across all disease areas. Adimab scientists will discover therapeutic antibody candidates to multiple targets nominated by Merck over a three-year period.

The company also announced the expansion of its existing research agreement with Lilly to include the discovery and optimization of multiple bispecific antibodies targeting molecular targets identified by Lilly.